CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
ZUMA-5（Axicabtagene Ciloleucel）与 SCHOLAR-5 在复发/难治性滤泡性淋巴瘤中的 3 年随访比较
英文原题：A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
查看英文原题
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在关键的ZUMA-5试验中，axicabtagene ciloleucel（axi-cel；一种自体抗CD19CAR-T 细胞疗法）在复发/难治性滤泡性淋巴瘤患者中显示出高比例的持久缓解。SCHOLAR-5是一个外部对照队列，旨在作为ZUMA-5的对照。在此，我们使用36个月随访数据和ZUMA-5的意向治疗人群，呈现ZUMA-5与SCHOLAR-5的更新比较分析。使用倾向评分方法，将ZUMA-5中的127例患者与SCHOLAR-5中的129例患者进行比较。在这一延长随访中，与历史上可用的治疗相比，axi-cel在该人群中继续显示出具有临床意义的生存获益。
展开英文摘要原文
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5.
Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5. At this extended follow-up, axi-cel continues to demonstrate clinically meaningful benefits in survival compared to historically available treatments in this population.
论文信息
- 作者
- Ghione P、Palomba ML、Ray MD、Limbrick-Oldfield EH、Owen J、Kanters S、Bobillo S、Ribiero MT
- 单位
- Memorial Sloan Kettering Cancer Center, New York, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: ghionep@mskcc.org.United States
- 文献类型
- 非美国政府资助研究 · 对照研究
- 期刊
- Clinical lymphoma, myeloma & leukemia2024 May
- 原文标识
- PubMed 38365528 · DOI 10.1016/j.clml.2024.01.011